Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections

Document Type

Article

Publication Date

7-1-2016

Publication Title

International journal of antimicrobial agents

Abstract

Extended-spectrum β-lactamase (ESBL) enzymes cause resistance to common β-lactam antibiotics and are associated with poor outcomes. Management of ESBL urinary tract infections (UTIs) is challenging given the limited treatment options available outside the hospital setting. In this study, the primary endpoint of UTI-related 30-day hospital re-admission or emergency department/clinic revisit rates was compared for fosfomycin and ertapenem outpatient ESBL UTI treatments. A retrospective cohort study was performed on patients with ESBL UTIs treated with outpatient fosfomycin or ertapenem from January 2010 to February 2015. Inclusion criteria were age ≥18 years, outpatient treatment with fosfomycin or ertapenem for symptomatic ESBL UTI, and positive urine cultures with microbiologically proven ESBL-producing bacteria. A non-inferiority margin of 0.15 was selected to detect a difference in the primary endpoint. Patient and infection characteristics were compared. A sensitivity analysis with propensity score matching was performed. In total, 178 patients were included (89 fosfomycin-treated and 89 ertapenem-treated). Ertapenem-treated patients received longer outpatient antibiotic treatment (10 days vs. 6 days; P

Medical Subject Headings

Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Female; Fosfomycin; Humans; Male; Middle Aged; Outpatients; Patient Readmission; Retrospective Studies; Treatment Outcome; Urinary Tract Infections; Young Adult; beta-Lactamases; beta-Lactams

PubMed ID

27234673

Volume

48

Issue

1

First Page

56

Last Page

60

Find It @ Sladen

Share

COinS